NO942660L - A method for determining cytolytic T cell precursors - Google Patents

A method for determining cytolytic T cell precursors

Info

Publication number
NO942660L
NO942660L NO942660A NO942660A NO942660L NO 942660 L NO942660 L NO 942660L NO 942660 A NO942660 A NO 942660A NO 942660 A NO942660 A NO 942660A NO 942660 L NO942660 L NO 942660L
Authority
NO
Norway
Prior art keywords
cells
cytolytic
precursors
pbmcs
characteristic
Prior art date
Application number
NO942660A
Other languages
Norwegian (no)
Other versions
NO942660D0 (en
Inventor
Pierre G Coulie
Thierry Boon
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO942660D0 publication Critical patent/NO942660D0/en
Publication of NO942660L publication Critical patent/NO942660L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En fremgangsmåte til bestemmelse av forstadier av cytolytiske T-celler og hyppigheten av disse forstadier, hvorved de cytolytiske T-celler som utvikles derav er spesifikke for antigener som er knyttet til eller karak- teristiske for tumorene. Fremgangsmåten omfatter at peri- fere blodmonocyttceller (PBMC) som inneholder prøve bringes i kontakt med en kilde for antigen som er karak- teristisk for eller knyttet til tumoren, såsom ikke-leve- dyktige tumorceller. Nevnte PBMCer, reagerer dersom de inneholder forstadier og det utvikles cytolytiske T- celler. Disse kan deretter bestemmes ved prøving av lysis av tumorceller som innføres i blandingen. Fremgangsmåten kan benyttes for å overvåke pasientrespons for forskjel- lige terapeutiske regimer.A method for determining the precursors of cytolytic T cells and the frequency of these precursors, whereby the cytolytic T cells developed therein are specific for antigens associated with or characteristic of the tumors. The method comprises contacting peripheral blood monocyte cells (PBMCs) with a source of antigen that is characteristic of or associated with the tumor, such as non-viable tumor cells. Said PBMCs, react if they contain precursors and develop cytolytic T cells. These can then be determined by testing the lysis of tumor cells introduced into the composition. The method can be used to monitor patient response to various therapeutic regimens.

NO942660A 1992-01-21 1994-07-15 A method for determining cytolytic T cell precursors NO942660L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82393392A 1992-01-21 1992-01-21
PCT/US1993/000083 WO1993014189A1 (en) 1992-01-21 1993-01-07 Method for determining cytolytic t cell precursors

Publications (2)

Publication Number Publication Date
NO942660D0 NO942660D0 (en) 1994-07-15
NO942660L true NO942660L (en) 1994-09-16

Family

ID=25240169

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942660A NO942660L (en) 1992-01-21 1994-07-15 A method for determining cytolytic T cell precursors

Country Status (8)

Country Link
EP (1) EP0624189A4 (en)
JP (1) JPH07503134A (en)
KR (1) KR950700402A (en)
AU (1) AU3435293A (en)
CA (1) CA2128424A1 (en)
FI (1) FI943422A0 (en)
NO (1) NO942660L (en)
WO (1) WO1993014189A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU664560B2 (en) * 1991-05-23 1995-11-23 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
US6322989B1 (en) 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US6352826B1 (en) 1991-11-25 2002-03-05 Yoreh Biotechnologies, Ltd. Method and kit for the detection of retroviral specific antibodies in seronegative individuals
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2188432C (en) 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
PT879282E (en) * 1996-01-17 2003-11-28 Imp College Innovations Ltd IMMUNOTHERAPY USING CITOTOXIC T-LYMPHOCYTES (CTL)
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
CA2272924A1 (en) * 1996-11-22 1998-05-28 Shiloov Medical Technologies Ltd. A whole blood/mitogen assay for the early detection of a subject with cancer and kit

Also Published As

Publication number Publication date
CA2128424A1 (en) 1993-07-22
FI943422A (en) 1994-07-19
EP0624189A1 (en) 1994-11-17
KR950700402A (en) 1995-01-16
FI943422A0 (en) 1994-07-19
AU3435293A (en) 1993-08-03
JPH07503134A (en) 1995-04-06
WO1993014189A1 (en) 1993-07-22
EP0624189A4 (en) 1995-05-17
NO942660D0 (en) 1994-07-15

Similar Documents

Publication Publication Date Title
NO861104L (en) PROCEDURE FOR DETERMINING THE MONOMER SEQUENCE IN MOLECULES.
NO942660L (en) A method for determining cytolytic T cell precursors
DK122184A (en) DEVICE FOR MICROBIOLOGICAL TESTING
DK393886A (en) MONOCLONE ANTIBODIES AND ANTIGEN FOR HUMAN NON-SMALL CELLAR LUNGCARCINOMES
FI873398A (en) EXAMINATION OF CLINICAL PARAMETERS WITH ENHANCED IMMUNOPROCESS.
EP0140379A3 (en) Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
ES511797A0 (en) "METHOD FOR TESTING ANTIGEN-ANTIBODY REACTIONS".
NO932320D0 (en) PROCEDURE FOR DETERMINING AN ANALYST IN A SAMPLE AND EQUIPMENT FOR THIS
DK199779A (en) CLEANED ANTIGEN FOR EXAMINATION OF NEISSERIA GONORRHOEAE ANTIBODIES
DE2965570D1 (en) Method for the detection and/or determination of an antigen specific immunoglobulin, immuno-reagents to be used in said method and test kit for said determination
DK344579A (en) DIAGNOSTIC AGENT AND PROCEDURE FOR DETECTING ANTIMITOCHONDRIAL OR ANTINUCLEAR ANTIBODIES
NO961138L (en) Protein kinase C activators and their use to reduce cell antigen expression
NO172910C (en) PROCEDURE FOR TESTING A TRIAL OF CELLS WITH REGARD TO THE PRESENTS OF THE CELL SURFACE ANTIGEN
FI862242A0 (en) MONOCLONAL ANTIKROPPAR FOER EJ-SMAOCELLIGA LUNGKRAEFTSVULSTER HOS MAENNISKA.
DK412184D0 (en) MOLECULATED CLONET DIAGNOSTIC PRODUCT AND PROCEDURE FOR IN VITRO DETECTION OF ANTIBODY OR ANTIGEN
ATE135468T1 (en) PRE-TESTING OF PROSTATE CANCER BY SERUM PROSTATIC SPECIFIC ANTIGEN
NO880835L (en) PROCEDURE AND APPARATUS FOR QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ANTIGENS, ANTIBODIES, MICROORGANISMS OR OTHER CELLS.
ES2187639T3 (en) ANALYSIS OF COMPETITIVE FIXATION FOR PLATELY ANTIGENS.
NO157358C (en) ANTIBODY REAGENT AND PROCEDURE FOR QUICK DETERMINATION OF PRESENCE OR REQUIREMENTS ON RED ANTIGEN BLOOD CELLS.
DK112980A (en) DIAGNOSIS PROCEDURE AND APPARATUS FOR IMPLEMENTING THE PROCEDURE
SE8603312D0 (en) SETTING TO MONITOR Fermentation
NO931613L (en) PROCEDURE FOR DETERMINATION OF SENSITY AND / OR ITS SPECIFIC IN AN TESTING SYSTEM FOR ANTIBODY DETECTION
NO921879L (en) PROCEDURE FOR MEASURING T-CELL SURFACE ANTIGENS IN HUMAN